CN Patent

CN115515592A — 施用恶拉戈利的方法

Assigned to AbbVie Inc · Expires 2022-12-23 · 3y expired

What this patent protects

本公开涉及GnRH受体拮抗剂用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合征(PCOS)或子宫腺肌病的用途。特别地，本公开描述了用于治疗此类妇科疾病的方法，其中该方法涉及施用恶拉戈利并且可以进一步涉及共同施用CYP2B6底物(例如，安非他酮)或CYP2C19底物(例如，奥美拉唑)。

USPTO Abstract

本公开涉及GnRH受体拮抗剂用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合征(PCOS)或子宫腺肌病的用途。特别地，本公开描述了用于治疗此类妇科疾病的方法，其中该方法涉及施用恶拉戈利并且可以进一步涉及共同施用CYP2B6底物(例如，安非他酮)或CYP2C19底物(例如，奥美拉唑)。

Drugs covered by this patent

Patent Metadata

Patent number: CN115515592A
Jurisdiction: CN
Classification: —
Expires: 2022-12-23
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.